News & Updates
Filter by Specialty:

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC
The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.
LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC
22 May 2023
Rheumatologists need to match patient’s health literacy, says study
Communication between physicians and patients with systemic lupus erythematosus (SLE) leaves a lot to be desired, with a recent study suggesting that rheumatologists must beef up communication to match the health literacy (HL) of their patients. Doing so may foster trust and improve self-management and outcomes in SLE.
Rheumatologists need to match patient’s health literacy, says study
22 May 2023
Natriuretic response to acetazolamide predicts decongestion in acute heart failure
A robust association exists between increased natriuresis and successful decongestion with acetazolamide in patients with acute decompensated heart failure (ADHF), suggests a study.
Natriuretic response to acetazolamide predicts decongestion in acute heart failure
22 May 2023
Dupilumab cuts exacerbations, improves lung function in paediatric asthma patients with high eosinophils
In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.
Dupilumab cuts exacerbations, improves lung function in paediatric asthma patients with high eosinophils
22 May 2023
Vitamin D supplementation exerts no effect on psoriasis severity in vitamin D-deficient individuals
Supplementation with vitamin D falls short of reducing psoriasis severity for individuals with 25-hydroxyvitamin D (25[OH]D) levels of <24 ng/mL, as reported in a study.
Vitamin D supplementation exerts no effect on psoriasis severity in vitamin D-deficient individuals
22 May 2023
Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC
In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.